US Bancorp DE Grows Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

US Bancorp DE lifted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,235 shares of the company’s stock after buying an additional 135 shares during the period. US Bancorp DE’s holdings in Medpace were worth $2,736,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of MEDP. State Street Corp boosted its position in Medpace by 7.2% in the third quarter. State Street Corp now owns 752,957 shares of the company’s stock worth $251,337,000 after purchasing an additional 50,312 shares during the last quarter. Geode Capital Management LLC boosted its position in Medpace by 7.6% in the third quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock worth $209,885,000 after purchasing an additional 44,371 shares during the last quarter. Wellington Management Group LLP boosted its position in Medpace by 36.0% in the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after purchasing an additional 109,886 shares during the last quarter. American Capital Management Inc. boosted its position in Medpace by 2.6% in the third quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock worth $127,060,000 after purchasing an additional 9,592 shares during the last quarter. Finally, GW&K Investment Management LLC boosted its position in Medpace by 93.9% in the fourth quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock worth $91,516,000 after purchasing an additional 133,379 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird lifted their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and an average price target of $381.44.

Medpace Trading Down 0.9 %

Shares of MEDP opened at $325.73 on Friday. The business’s 50 day moving average is $341.27 and its 200 day moving average is $344.03. The company has a market capitalization of $9.92 billion, a PE ratio of 25.79, a price-to-earnings-growth ratio of 3.81 and a beta of 1.36. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.